calprotectin Archives - Page 3 of 8 - Buhlmann Diagnostics Corp

Tag: calprotectin

IBDoc and Me

Health Canada Licence: 98903, Device class: 3  IBDoc® is not available for sale in the US. Read perspectives and insights from a patient from the UK who has been using IBDoc®  since last October and is trying this new tool to monitor his Crohn’s Disease.  He has been documenting his experiences in a blog to share his
Continue Reading

BUHLMANN LabSense News Winter 2018 Edition

BUHLMANN Diagnostics Corp is proud to release the sixth edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News. Check Out LabSense News Today! What's New Introducing BAT in Food Allergy Webinar recording and eBook by Dr. Alexandra Santos as well as two new IBDoc®  Posters
Continue Reading

Evaluation of the BÜHLMANN fCAL® turbo Test at City Hospital Triemli in Zurich

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 French Version INTERVIEW WITH ANITA GRÜNAUER AND PREDRAG NESIC, City Hospital Triemli, Zurich Mrs. Grünauer and Mr. Nesic, several months ago you decided to implement the BÜHLMANN fCAL® turbo on your Roche cobas® c501 system. Can
Continue Reading

BUHLMANN LabSense News: Fall 2017 Edition

BUHLMANN Diagnostics Corp is proud to release the fifth edition of our newsletter. View the latest information, new happenings, products highlights, citations, and promotions in the BUHLMANN LabSense News. You won’t want to miss some interesting highlights for the Flow CAST® assay including interesting videos, ebooks and more in this edition! Check Out LabSense News Today! VIEW
Continue Reading

Exploration of Predictive Biomarkers of Early IFX Response in Acute Severe Colitis: A Prospective Pilot Study

BÜHLMANN fCAL® ELISA Citation:  Beswick, L. et al. Exploration of predictive biomarkers of early IFX response in acute severe colitis: A prospective pilot study.  Journal of Crohn's and Colitis. 2017 Nov 7. DOI: 10.1093/ecco-jcc/jjx146.  PMID:  29121178 . Highlight from this Publication “In ASUC, post-first dose IFX, early assessment of serum/faecal IFX, calprotectin and partial Mayo scores can accurate predict future
Continue Reading

Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis

BÜHLMANN fCAL® ELISA: Kristensen, V., A. Roseth, et al.  Fecal Calprotectin: A Reliable Predictor of Mucosal Healing after Treatment for Active Ulcerative Colitis.  Gastroenterology Research and Practice; Volume 2017 (2017), Article ID 2098293, 5 pages.  DOI: 10.1155/2017/2098293. Highlights from this Publication “Conclusions. Fecal calprotectin <250 μg/g after medical treatment for active ulcerative colitis is a reliable marker of endoscopic
Continue Reading

Diagnostic Accuracy of Fecal Calprotectin in Assessing the Severity of Inflammatory Bowel Disease: From Laboratory to Clinic

BÜHLMANN fCAL® ELISA: S. Moein, D. Quujeq et al. Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic. Caspian J Intern Med 2017; 8(3):178-182 DOI: 10.22088/cjim.8.3.178. Highlights from this Publication “ The current study also suggested 78.4 µg/g as the cut-off level for FC by 100% sensitivity and
Continue Reading

Announcing Enhancement to Quantum Blue® fCAL (Calprotectin) High Range Assay

Quantum Blue® fCAL High Range Enhancements BUHLMANN is happy to introduce a revised and enhanced version of our Quantum Blue® fCAL high range test (LF-CHR25) to the market.  The changes result in several beneficial features that not only further simplify the procedure but also improve performance characteristics.   Enhancements and Benefits: Sample dilution NOW in extraction
Continue Reading

Come Visit BUHLMANN at AMLI 2017- Booth #13

     AMLI 2017 BUHLMANN Diagnostics Corp  Booth: #13 August 13 - 16, 2017 Renaissance Stapleton Hotel | Denver, C0 LEARN MORE Click & Contact our AMLI 2017BUHLMANN Team Connect with our team ahead of time, learn more about the BÜHLMANN's Products and Solutions or schedule a meeting! Jennifer Stuart, Technical Sales Specialist JENNIFER STUART Technical Sales Specialist jls@buhlmannlabs.com
Continue Reading

Turbo Charged from the Start: Introducing in-house Calprotectin Testing Directly on the Roche cobas® c702

Rosie Forster, Queen Elizabeth Hospital Birmingham, with the CALEX and Roche cobas c702 BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 Rosie Forster and Karen Smith, Clinical Biochemistry, Queen Elizabeth Hospital Birmingham introduce Faecal Calprotectin testing into their laboratory using the BÜHLMANN
Continue Reading